EcoDrugPlus

Cytidine Deaminase-Like

Ensembl ID : ENSDCDG00000026703
Gene Symbol: LOC114801014
3 Cross references
195 Possible Orthologues:

Cytochrome P450 26a1

Ensembl ID : ENSDCDG00000018153
Gene Symbol: LOC114784319
3 Cross references
195 Possible Orthologues:

Cytochrome P450 3a27-Like

Ensembl ID : ENSDCDG00000008452
Gene Symbol: LOC114793388
3 Cross references
565 Possible Orthologues:

Cytochrome P450 3a30-Like

Ensembl ID : ENSDCDG00000014525
Gene Symbol: LOC114785728
3 Cross references
608 Possible Orthologues:

Cytochrome P450 Family 19 Subfamily A Member 1

Ensembl ID : ENSDCDG00000028928
Gene Symbol: CYP19A1
3 Cross references
246 Possible Orthologues:

Delta-Type Opioid Receptor-Like

Ensembl ID : ENSDCDG00000016756
Gene Symbol: LOC114795861
3 Cross references
215 Possible Orthologues:

Delta-Type Opioid Receptor-Like

Ensembl ID : ENSDCDG00000008450
Gene Symbol: LOC114771708
2 Cross references
197 Possible Orthologues:

Delta-Type Opioid Receptor-Like

Ensembl ID : ENSDCDG00000018122
Gene Symbol: LOC114790044
3 Cross references
138 Possible Orthologues:

Delta-Type Opioid Receptor-Like

Ensembl ID : ENSDCDG00000013493
Gene Symbol: LOC114788082
3 Cross references
200 Possible Orthologues:

Diacylglycerol O-Acyltransferase 1

Ensembl ID : ENSDCDG00000009258
Gene Symbol: DGAT1
3 Cross references
187 Possible Orthologues:

Diacylglycerol O-Acyltransferase 1-Like

Ensembl ID : ENSDCDG00000025658
Gene Symbol: LOC114773584
3 Cross references
187 Possible Orthologues:

Diacylglycerol O-Acyltransferase 1-Like

Ensembl ID : ENSDCDG00000033086
Gene Symbol: LOC114770650
3 Cross references
192 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).